BioNTech to buy CureVac in $1.25 billion deal, saying it will bolster cancer work

Taking stock of the drug industry, from the lab to the medicine chest

June 12, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

THOMAS KIENZLE/AFP via Getty Images STAT+ | BioNTech to buy CureVac in $1.25 billion deal, saying it will bolster cancer work The onetime competitor in the Covid-19 vaccine race see a "shared commitment" to the potential of mRNA technology. By Andrew Joseph STAT+ | Insmed is an attractive, but expensive takeout meal In this week's edition of "Adam's Biotech Scorecard," Adam also asked whether Regeneron's troubles are in the rearview mirror. By Adam Feuerstein STAT+ | A closer look at the new members of the CDC vaccine advisory panel HHS Secretary Kennedy, after firing every member of key CDC vaccine advisory panel, appoints eight new members, including critics of mRNA technology. By STAT Staff

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser